Profound Medical (NASDAQ:PROF) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Profound Medical (NASDAQ:PROF) from a sell rating to a hold rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Several other equities analysts have also issued reports on PROF. Raymond James Financial raised shares of Profound Medical from an “outperform” rating to a “strong-buy” rating and set a $11.00 price target for the company in a report on Monday, July 27th. Weiss Ratings raised Profound Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Profound Medical has a consensus rating of “Moderate Buy” and an average target price of $11.50.

Profound Medical Price Performance

Shares of NASDAQ:PROF opened at $6.90 on Friday. Profound Medical has a one year low of $4.80 and a one year high of $8.95. The stock has a market cap of $252.26 million, a price-to-earnings ratio of -7.04 and a beta of 0.75. The company has a 50 day moving average of $6.57 and a 200-day moving average of $6.69.

Profound Medical (NASDAQ:PROF) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.04). The company had revenue of $2.48 million during the quarter, compared to analyst estimates of $4.75 million. Profound Medical had a negative net margin of 171.57% and a negative return on equity of 63.03%. Equities research analysts anticipate that Profound Medical will post -0.79 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Gagnon Securities LLC increased its position in shares of Profound Medical by 12.2% during the fourth quarter. Gagnon Securities LLC now owns 1,944,061 shares of the company’s stock worth $15,300,000 after acquiring an additional 211,021 shares in the last quarter. Ardsley Advisory Partners LP raised its stake in shares of Profound Medical by 36.4% in the 4th quarter. Ardsley Advisory Partners LP now owns 450,000 shares of the company’s stock valued at $3,542,000 after purchasing an additional 120,000 shares during the period. Connective Capital Management LLC bought a new stake in shares of Profound Medical in the fourth quarter valued at about $787,000. Gagnon Advisors LLC boosted its position in shares of Profound Medical by 7.3% during the fourth quarter. Gagnon Advisors LLC now owns 962,186 shares of the company’s stock worth $7,572,000 after buying an additional 65,515 shares during the period. Finally, Annis Gardner Whiting Capital Advisors LLC acquired a new position in shares of Profound Medical during the first quarter worth about $259,000. Institutional investors own 47.86% of the company’s stock.

Trending Headlines about Profound Medical

Here are the key news stories impacting Profound Medical this week:

• Positive Sentiment: Raised Q3 revenue outlook: Profound Medical increased its third-quarter 2026 revenue outlook to a level above Wall Street expectations. The update helped drive a 21.7% share-price surge in the prior session and suggests stronger near-term commercial momentum for the TULSA-PRO platform. Profound Medical raises Q3 2026 revenue outlook above estimates
• Positive Sentiment: Telix co-education agreement: Profound and Telix Pharmaceuticals (ASX: TLX; NASDAQ: TLX) will educate urologists, radiologists, nuclear-medicine specialists and prostate-cancer centers on combining Telix’s PSMA-PET imaging products, Gozellix and Illuccix, with Profound’s MRI-guided, AI-powered TULSA-PRO treatment. The agreement could expand Profound’s access to urologists, support evidence-based patient selection and strengthen adoption of its prostate-treatment system. No financial terms were disclosed. Profound Medical and Telix Pharmaceuticals enter co-education agreement
• Neutral Sentiment: Analyst momentum remains uncertain: Coverage highlighted the improved revenue outlook and a rating upgrade, but noted that recent earnings-estimate revisions may not translate into additional near-term gains after the stock’s substantial rally. Profound Medical Q3 revenue beats outlook
• Neutral Sentiment: Short-interest data offers little signal: Reported short interest was zero shares as of October 9, with a zero-day days-to-cover ratio. While described as an increase, the figure does not indicate meaningful short-covering pressure or a likely short squeeze.

About Profound Medical

Profound Medical Corp. (NASDAQ:PROF) is a medical technology company focused on developing and commercializing incisionless therapies for localized prostate disease. The company’s flagship product is the TULSA-PRO system, which uses real-time magnetic resonance imaging (MRI) guidance and transurethral ultrasound to deliver controlled thermal ablation to targeted prostate tissue.

TULSA-PRO is designed to enable physicians to customize treatment based on a patient’s prostate anatomy and disease location.